uniQure N.V. (QURE) stock
QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30224% above fair value
$20.30−0.48 (-2.31%)
Close on Nov 18, 2026Market cap $1.41BP/E –Yield –
uniQure r&d expenses
Research and development expenses are spending on new products and technology.
uniQure's R&D Expenses for the twelve months ending Jun 30, 2026 was $132.29M, down 6.1% year over year. For fiscal 2025 it was $140.67M, down 2.2% from the year before. Over ten years it grew 9.1% a year on average. The highest annual figure on record is $214.86M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.67M | -2.2% |
| FY2024 | Dec 31, 2024 | $143.78M | -33.1% |
| FY2023 | Dec 31, 2023 | $214.86M | +8.7% |
| FY2022 | Dec 31, 2022 | $197.59M | +37.6% |
| FY2021 | Dec 31, 2021 | $143.55M | +17.3% |
| FY2020 | Dec 31, 2020 | $122.40M | +29.2% |
| FY2019 | Dec 31, 2019 | $94.74M | +26.6% |
| FY2018 | Dec 31, 2018 | $74.81M | +3.7% |
| FY2017 | Dec 31, 2017 | $72.17M | -0.5% |
| FY2016 | Dec 31, 2016 | $72.51M | +22.6% |
| FY2015 | Dec 31, 2015 | $59.13M | +35.1% |
| FY2014 | Dec 31, 2014 | $43.77M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $33.96M | -4.0% |
| Q1 FY2026 | Mar 31, 2026 | $29.18M | -19.3% |
| Q4 FY2025 | Dec 31, 2025 | $34.78M | -10.4% |
| Q3 FY2025 | Sep 30, 2025 | $34.37M | +12.3% |
| Q2 FY2025 | Jun 30, 2025 | $35.38M | +5.1% |
| Q1 FY2025 | Mar 31, 2025 | $36.14M | -11.2% |
| Q4 FY2024 | Dec 31, 2024 | $38.84M | -8.9% |
| Q3 FY2024 | Sep 30, 2024 | $30.60M | -53.2% |
| Q2 FY2024 | Jun 30, 2024 | $33.66M | -26.9% |
| Q1 FY2024 | Mar 31, 2024 | $40.69M | -33.1% |
| Q4 FY2023 | Dec 31, 2023 | $42.62M | -26.9% |
| Q3 FY2023 | Sep 30, 2023 | $65.40M | +36.1% |
| Q2 FY2023 | Jun 30, 2023 | $46.04M | -0.3% |
| Q1 FY2023 | Mar 31, 2023 | $60.81M | +35.1% |
| Q4 FY2022 | Dec 31, 2022 | $58.33M | +37.8% |
| Q3 FY2022 | Sep 30, 2022 | $48.07M | +31.9% |
| Q2 FY2022 | Jun 30, 2022 | $46.19M | +41.1% |
| Q1 FY2022 | Mar 31, 2022 | $45.00M | +37.8% |
| Q4 FY2021 | Dec 31, 2021 | $42.34M | +33.6% |
| Q3 FY2021 | Sep 30, 2021 | $36.43M | +0.4% |
| Q2 FY2021 | Jun 30, 2021 | $32.75M | +15.3% |
| Q1 FY2021 | Mar 31, 2021 | $32.66M | +25.5% |
| Q4 FY2020 | Dec 31, 2020 | $31.68M | +19.6% |
| Q3 FY2020 | Sep 30, 2020 | $36.30M | +54.1% |
| Q2 FY2020 | Jun 30, 2020 | $28.40M | +17.6% |
| Q1 FY2020 | Mar 31, 2020 | $26.01M | +26.7% |
| Q4 FY2019 | Dec 31, 2019 | $26.49M | +41.5% |
| Q3 FY2019 | Sep 30, 2019 | $23.55M | +14.7% |
| Q2 FY2019 | Jun 30, 2019 | $24.15M | +30.6% |
| Q1 FY2019 | Mar 31, 2019 | $20.54M | +20.4% |
| Q4 FY2018 | Dec 31, 2018 | $18.72M | +2.8% |
| Q3 FY2018 | Sep 30, 2018 | $20.54M | +2.2% |
| Q2 FY2018 | Jun 30, 2018 | $18.49M | +9.6% |
| Q1 FY2018 | Mar 31, 2018 | $17.06M | +0.4% |
| Q4 FY2017 | Dec 31, 2017 | $18.21M | -8.9% |
| Q3 FY2017 | Sep 30, 2017 | $20.10M | +21.1% |
| Q2 FY2017 | Jun 30, 2017 | $16.87M | – |
| Q1 FY2017 | Mar 31, 2017 | $16.99M | – |
| Q4 FY2016 | Dec 31, 2016 | $19.98M | – |
| Q3 FY2016 | Sep 30, 2016 | $16.60M | – |
See a number that looks wrong?